FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Released May 18, 2017

Focus on Women's and Men’s Health

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

There are real differences in men's and women's health concerns. The life expectancy gap is decreasing between men and women, but men still deal with higher rates of cardiovascular disease, prostate and testicular cancers, fluctuating testosterone levels, and fertility issues. Women’s health issues include cancer, reproductive and sexual health issues, osteoporosis prevention and management, nutrition and sports medicine. This series focuses on new developments in the diagnosis and treatment of gender-specific health issues.

About

Focus on Women's and Men’s Health